Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
Un diagnóstico de fibrosis quística no debe descalificar a una persona para recibir atención que pueda salvarle la vida.
More than 160 organizations join the Cystic Fibrosis Foundation in asking Congress to expand paid family and medical leave for people with chronic conditions, such as cystic fibrosis.
The Cystic Fibrosis Foundation has joined 11 other patient groups in filing an amicus brief to challenge the short-term, limited-duration health insurance rule, which threatens access to adequate, affordable coverage for people with cystic fibrosis.
Responding to the U.S. Department of Health and Human Services final rule on short-term, limited-duration insurance plans, the Cystic Fibrosis Foundation joined 26 other nonpartisan patient and consumer groups to voice concern that these plans will split the market and jeopardize access to affordable, adequate health care for people living with pre-existing conditions.
The Department of Justice's decision to no longer defend critical provisions of the Affordable Care Act (ACA) risks health insurance coverage for people with cystic fibrosis and other pre-existing conditions.
A group of nonpartisan patient and consumer organizations issued a statement after passage of the Tax Cuts and Jobs Act.
The organizations urge continued protections for patients.
Patient and provider groups urge safeguard for the health and lives of millions of Americans with a bipartisan approach to reform.